Concentrix Corporation : The decline is still in force
Entry price | Target | Stop-loss | Potential |
---|
US$120.78 |
US$92.9 |
US$126.5 |
+23.08% |
---|
The declining trend in the stock price that has been seen for a number of trading sessions, should not be expected to reach a turning point over the coming days.
Summary● On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths● Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
● The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
● Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
● The group usually releases upbeat results with huge surprise rates.
Weaknesses● The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
● The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
● Over the past twelve months, analysts' opinions have been revised negatively.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.